Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombotic Microangiopathies | 10 | 2025 | 49 | 3.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2025 | 1273 | 2.310 |
Why?
|
| Complement Pathway, Alternative | 6 | 2019 | 14 | 1.960 |
Why?
|
| Venous Thromboembolism | 6 | 2026 | 191 | 1.600 |
Why?
|
| Pulmonary Embolism | 4 | 2024 | 182 | 1.590 |
Why?
|
| Thrombosis | 9 | 2024 | 498 | 1.380 |
Why?
|
| Anticoagulants | 8 | 2026 | 598 | 1.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2022 | 52 | 1.000 |
Why?
|
| Kidney Glomerulus | 2 | 2018 | 80 | 0.990 |
Why?
|
| Endothelial Cells | 4 | 2018 | 520 | 0.890 |
Why?
|
| Stem Cell Transplantation | 1 | 2025 | 224 | 0.820 |
Why?
|
| Hemorrhage | 3 | 2025 | 485 | 0.790 |
Why?
|
| Plasma Exchange | 2 | 2024 | 86 | 0.730 |
Why?
|
| Warfarin | 1 | 2023 | 123 | 0.720 |
Why?
|
| Complement Activation | 2 | 2019 | 50 | 0.690 |
Why?
|
| Child | 28 | 2026 | 26171 | 0.660 |
Why?
|
| Neuroblastoma | 1 | 2025 | 547 | 0.640 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 332 | 0.630 |
Why?
|
| Complement C3b | 1 | 2019 | 7 | 0.620 |
Why?
|
| Complement Factor B | 1 | 2019 | 10 | 0.620 |
Why?
|
| Patient Care Team | 1 | 2024 | 558 | 0.600 |
Why?
|
| Microvessels | 2 | 2020 | 58 | 0.560 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 467 | 0.480 |
Why?
|
| Protein C | 1 | 2015 | 17 | 0.470 |
Why?
|
| Biomarkers | 3 | 2024 | 3358 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 566 | 0.440 |
Why?
|
| Thrombolytic Therapy | 4 | 2025 | 191 | 0.440 |
Why?
|
| Adolescent | 15 | 2026 | 20797 | 0.390 |
Why?
|
| Humans | 39 | 2026 | 130055 | 0.370 |
Why?
|
| Retrospective Studies | 13 | 2026 | 17538 | 0.360 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 191 | 0.360 |
Why?
|
| Child, Preschool | 11 | 2026 | 15005 | 0.350 |
Why?
|
| Vena Cava, Inferior | 2 | 2021 | 94 | 0.320 |
Why?
|
| Infant | 10 | 2026 | 13266 | 0.310 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 164 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 848 | 0.300 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2022 | 33 | 0.290 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2021 | 103 | 0.290 |
Why?
|
| Alligators and Crocodiles | 1 | 2008 | 1 | 0.290 |
Why?
|
| Amputation, Traumatic | 1 | 2008 | 9 | 0.290 |
Why?
|
| Arm Injuries | 1 | 2008 | 15 | 0.290 |
Why?
|
| Bites and Stings | 1 | 2008 | 29 | 0.280 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 3 | 2018 | 13 | 0.280 |
Why?
|
| Debridement | 1 | 2008 | 91 | 0.280 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2025 | 8 | 0.260 |
Why?
|
| Brain | 1 | 2018 | 3146 | 0.230 |
Why?
|
| Transplantation, Autologous | 1 | 2025 | 253 | 0.220 |
Why?
|
| Sarcoma, Ewing | 1 | 2026 | 121 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 636 | 0.210 |
Why?
|
| Male | 15 | 2026 | 64375 | 0.210 |
Why?
|
| Adult | 9 | 2025 | 30999 | 0.200 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 45 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 208 | 0.190 |
Why?
|
| Osteosarcoma | 1 | 2026 | 275 | 0.190 |
Why?
|
| Health Information Systems | 1 | 2022 | 34 | 0.180 |
Why?
|
| Blood Coagulation Disorders | 1 | 2023 | 103 | 0.180 |
Why?
|
| Female | 13 | 2026 | 70227 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2022 | 93 | 0.180 |
Why?
|
| Aortic Diseases | 2 | 2024 | 187 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 470 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 324 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2024 | 397 | 0.160 |
Why?
|
| Risk Factors | 5 | 2026 | 10956 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2021 | 184 | 0.150 |
Why?
|
| Young Adult | 6 | 2025 | 9978 | 0.140 |
Why?
|
| Lung | 2 | 2024 | 1531 | 0.140 |
Why?
|
| Immunoassay | 2 | 2015 | 124 | 0.140 |
Why?
|
| Complement Factor H | 2 | 2015 | 24 | 0.140 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2018 | 13 | 0.140 |
Why?
|
| Complement C3a | 1 | 2018 | 18 | 0.140 |
Why?
|
| Complement C5a | 1 | 2018 | 18 | 0.140 |
Why?
|
| Receptors, Complement | 1 | 2018 | 34 | 0.130 |
Why?
|
| Inpatients | 1 | 2022 | 557 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 2 | 2015 | 304 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 182 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 271 | 0.130 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 413 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2574 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12821 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2548 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2023 | 5033 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1482 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 348 | 0.110 |
Why?
|
| Hospitalization | 1 | 2024 | 1935 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 411 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2018 | 401 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 700 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2015 | 64 | 0.110 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 100 | 0.110 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 59 | 0.110 |
Why?
|
| Prognosis | 2 | 2023 | 4845 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2015 | 169 | 0.100 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 527 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2015 | 248 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 125 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2015 | 409 | 0.100 |
Why?
|
| Gene Expression | 1 | 2018 | 1482 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 525 | 0.100 |
Why?
|
| Hemostasis | 2 | 2025 | 76 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2015 | 765 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2015 | 317 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1375 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3349 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2885 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 656 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 1478 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5164 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8547 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1097 | 0.070 |
Why?
|
| Graft vs Host Disease | 2 | 2024 | 688 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2008 | 175 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2025 | 235 | 0.060 |
Why?
|
| Hematology | 1 | 2025 | 42 | 0.050 |
Why?
|
| Reference Values | 1 | 2025 | 674 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1112 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2023 | 38 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 43 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2024 | 117 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 58 | 0.050 |
Why?
|
| Autopsy | 1 | 2023 | 113 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 65 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 79 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 201 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1874 | 0.040 |
Why?
|
| Immunization | 1 | 2022 | 269 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 263 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 280 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 521 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2025 | 791 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 370 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 360 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1240 | 0.040 |
Why?
|
| Microcirculation | 1 | 2020 | 104 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 165 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2891 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 551 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2022 | 810 | 0.030 |
Why?
|
| Communication | 1 | 2022 | 539 | 0.030 |
Why?
|
| Texas | 1 | 2026 | 3655 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 215 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 800 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1264 | 0.030 |
Why?
|
| Weibel-Palade Bodies | 1 | 2015 | 1 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2015 | 35 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 43 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2015 | 47 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2822 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 95 | 0.030 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 20 | 0.030 |
Why?
|
| Medical Records | 1 | 2015 | 174 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 33660 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1130 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 6165 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1481 | 0.020 |
Why?
|
| United States | 1 | 2025 | 11893 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2290 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3740 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 28303 | 0.010 |
Why?
|